Reach Us +1-217-403-9671
Distinct Perturbation Of The Translatome By The Anti-diabetic Drug Metformin | 3721
ISSN: 0974-276X

Journal of Proteomics & Bioinformatics
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Distinct perturbation of the translatome by the anti-diabetic drug metformin

2nd International Conference on Proteomics & Bioinformatics

Ola Larsson

ScientificTracks Abstracts: J Proteomics Bioinform

DOI: 10.4172/0974-276X.S1.060

Reduced cancer incidence has been reported among type II diabetics treated with metformin. Laboratory models have demonstrated that metformin has anti-proliferative and anti-neoplastic effects associated with inhibition of mTORC1, but the sequellae of this inhibition are poorly understood. Here we show that metformin regulates gene expression at the level of mRNA translation, to an extent comparable to canonical mTOR inhibitors (rapamycin and PP242), and that its anti-proliferative activity involves selective translational suppression of mRNAs encoding cell cycle regulators via the mTORC1/4E-BP pathway. Thus metformin is a selective inhibitor of mRNA translation and thereby affects the proteome, suggesting applications in cancer prevention and treatment.
Ola Larsson completed his Ph.D at Karolinska Institutet and, following postdoctoral studies at University of Minnesota and McGill University, is currently an assistant professor at Karolinska Insitute Department of Oncology-Pathology. He has published more than 35 papers in reputed journals.
Leave Your Message 24x7